• Tofacitinib: From JAK Blockade to Mitochondrial Repair

  2026-09-10

  A mechanistic perspective on how Tofacitinib and CP-690550 connect JAK/STAT inhibition with GM-CSF-driven macrophage inflammation, mitochondrial dysfunction, and translational assay design in rheumatoid arthritis research.

• Wortmannin Workflows for PI3K Signaling Research

  2026-09-10

  Wortmannin combines powerful PI3K pathway suppression with a practical way to interrogate endocytosis, autophagy, apoptosis, and cancer phenotypes. This workflow-focused guide connects pathway pharmacology with the reference study’s viral-entry assays while highlighting controls, dosing logic, and troubleshooting safeguards.

• GSK2606414 for PERK-Driven ER Stress Research

  2026-09-09

  GSK2606414 is a high-potency PERK inhibitor for separating PERK-dependent signaling from broader ER stress responses. This practical guide translates a TMAO-induced zebrafish NAFLD study into cell-based, biochemical, and translational workflows with dosing, controls, and troubleshooting guidance.

• SmCPK20–SmWRKY2 Control of Tanshinone Synthesis

  2026-09-08

  The reference study identifies a jasmonate–calcium signaling module in which SmCPK20 phosphorylates SmWRKY2 at Thr-256, increasing SmCPS1 promoter activation and tanshinone accumulation in Salvia miltiorrhiza. Its main contribution is to connect JAZ-mediated transcriptional release with a phosphorylation-dependent transcription-factor switch, providing a mechanistic framework for studying protein phosphorylation signaling in plant specialized metabolism.

• Phosbind Acrylamide for Phosphorylation Analysis

  2026-09-08

  Phosbind Acrylamide enables antibody-free separation of phosphorylated and non-phosphorylated proteins by phosphate-dependent mobility shifts in SDS-PAGE. This guide connects the assay to inflammasome signaling research, offering an executable workflow, optimization checkpoints, and clear limits for interpreting phosphorylation evidence.

• Stattic and the NF-κB–IL6–STAT3 Axis

  2026-09-07

  Stattic is a selective STAT3 inhibitor for studying how inflammatory signals drive tumor survival, resistance, and transcriptional reprogramming. This article translates findings from a gut dysbiosis–prostate cancer study into context-aware assay strategies for HNSCC research and cancer biology.

• Imatinib (STI571) Experimental Workflow Guide

  2026-09-07

  Translate Imatinib target inhibition into reproducible kinase, proliferation, and erythroleukemia assays with concentration, exposure, and readout choices grounded in mechanism. The workflow also shows how the compound can test Abl-linked effects alongside the HIF-α/GATA1 biology highlighted in recent K562 research.

• BMX-IN-1: From Kinase Probe to Lysosome Biology

  2026-09-05

  BMX-IN-1 is a selective, irreversible BMX kinase inhibitor for dissecting cancer signaling and host–pathogen biology. This article explains how recent mechanistic evidence connects BMX activity with ATP6V1E1 phosphorylation, lysosomal acidification, and Mycobacterium tuberculosis survival.

• (Z)-4-Hydroxytamoxifen in Reliable Assays

  2026-09-04

  This scenario-driven guide explains how (Z)-4-Hydroxytamoxifen (SKU B5421) can improve experimental control in estrogen-receptor assays, from solvent handling to interpretation of viability and proliferation data. It connects practical assay design with breast cancer relapse research while distinguishing documented product properties from workflow recommendations.

• PHF2 Drives Neuroinflammation in Alzheimer’s Disease

  2026-09-04

  A 2025 Molecular Psychiatry study identifies the histone demethylase PHF2/KDM7C as an upstream regulator of inflammatory gene expression in Alzheimer’s disease. By combining human tissue, patient-derived neurons, genomic profiling, and 5xFAD experiments, the authors connect PHF2 reduction with lower glial activation, improved glutamatergic synaptic function, and better spatial memory.

• CircRHOBTB3, NONO, and MAOA in Prostate Cancer

  2026-09-03

  A 2025 Cancer Letters study identifies circRHOBTB3 as a downregulated tumor-suppressive circular RNA in prostate cancer and defines a circRNA–NONO–MAOA pathway controlling proliferation and metastasis. Its combination of metastatic-model sequencing, RNA localization, protein-interaction, transcriptional, and functional assays provides a useful framework for studying RNA-mediated regulation in advanced prostate cancer.

• EDI3 Inhibition in HER2-Resistant Breast Cancer

  2026-09-03

  Keller et al. identify the glycerophosphodiesterase EDI3/GPCPD1 as a metabolic vulnerability in ER-HER2-positive breast cancer, particularly after resistance to HER2-targeted treatment. Their combination of patient-tissue analysis, pathway perturbation, cell studies, and xenograft experiments supports EDI3 inhibition as a strategy for reducing viability and tumor growth, while also defining important limits for translation.

• Lactate, GPR81, and Insulin-Independent Glucose Uptake

  2026-09-02

  A 2026 Cell Research study identifies lactate as an insulin-independent regulator of skeletal-muscle glucose uptake and defines a GPR81–FARP1–RAC1–GLUT4 mechanism linking exercise metabolism to glucose control. Its genetic, pharmacological, metabolic, and human-association evidence suggests that GPR81 may complement insulin signaling, while also highlighting important boundaries for translating the pathway into therapeutic research.

• Recombinant Human IL-15 in Neuroimmune Assays

  2026-09-02

  Recombinant Human IL-15 provides a controlled immune perturbation for T-cell and NK-cell experiments. This article connects IL-15 assay design with new findings on early-life adversity, oxytocin signaling, and innate defensive behavior while defining the limits of that cross-domain interpretation.

• Perospirone (SM-9018 Free Base) Research Workflows

  2026-09-01

  Build receptor-centered schizophrenia research assays while accounting for a newly characterized vascular Kv1.5-related off-target effect. This practical guide shows how to prepare Perospirone, separate receptor pharmacology from ion-channel activity, and troubleshoot concentration, solvent, and electrophysiology variables.

8446 records 8/564 page Previous Next First page 上5页 678910 下5页 Last page